Generex Biotechnology Corp. (fka GNBTQ)

[Solar_Express]

Covid-19/Generex Receives 5M Contract From Four Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines



https://generex.com/index.html

World Health Org/Generex-EpiVax/Li Key Peptide Vaccine/PDF/Pg 2 https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1



NGIO/Generex Sub/S1 NASDAQ Upcoming Listing/Formerly Antigen Express/Website https://www.nugenerexdiagnostics.com/

------------------------------------------------------------------

Terms approved to proceed with collaborative effort with international consortium

MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has received a contract from the China Technology Exchange, Beijing Zhonghua Investment Fund Management Co., LTD., Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD. The terms of the contract, which have been agreed to in writing by both parties, include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced.

Joe Moscato, President & Chief Executive Officer of Generex has signed the draft contract with deal terms and will be traveling to China next week to sign the final, official contract with its Chinese partners to develop a COVID-19 vaccine using the Ii-Key immune system activation technology. Generex management will be presenting the company’s data, demonstrating the technology, and finalizing work plans with those partners to produce an Ii-Key-COVID-19 peptide vaccine that can be tested in human studies within 90 days. Mr. Moscato is expected to sign the official agreements on behalf of Generex at a signing ceremony in China next week, at which time Generex will make further announcements.

Mr. Moscato said, “Our subsidiary NuGenerex Immuno-Oncology (NGIO) "Future NASDAQ Listing" has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”

https://www.pharmaceutical-technology.com/news/generex-covid-19-vaccine/

http://www.globenewswire.com/news-release/2020/02/27/1992098/0/en/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html

------------------------------------------------------------------



https://epivax.com/

Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic

Coronavirus nCOV-2019 antigenic epitopes predicted by EpiVax computational vaccinology and epitope prediction tools to be linked with Ii-Key to generate peptide vaccines against COVID-19

1. EpiVax will be using the the Covid-19 vaccine and will be developed using Generex’s li-Key immune system activation technology.
2. EpiVax worked for 21 years to be able to make a vaccine in 24 hours! (From EpiVax web site)
https://www.pharmaceutical-technology.com/news/generex-covid-19-vaccine/
3. EpiVax private biopharm company is working in collaborarion with Generex.
4. GNBT has signed a contract with EpiVax.
https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic
5. EpiVax doing lab work both in Wuhan, China and Ross Labs at the University of Georgia.
6. EpiVax has solicited funds from NIH and has received funds from NIH in the past.
7. Generex will be doing human trials soon in China. Will test on human subjects who had the Covid-19 virus in the past. If successful, FDA will be under pressure to approve the vaccine fast.
8. This all translates to GNBT being a huge winner way ahead of the other labs.

-----------------------------------------------------------------

Biotech Stock News: Generex Biotechnology (OTCQB: GNBT) Announces Corporate Update and Investor Conference Call: Addressing the #Coronavirus Pandemic with Ii-Key Peptide Vaccines - Thursday February 13 https://www.investorideas.com/news/2020/biotech/02103OTCQBGNBT-Coronavirus.asp

-----------------------------------------------------------------

Generex Biotechnology Investing DD 2020

1) The CEO Joe Moscato is a marketing guy and he knows how to get everyone to see the big picture and to take long term views. Even if it means taking less pay now for rewards later. Including himself. No big fat salary for Joe now. In fact he has pretty much deferred any salary. What CEO does that?

2) GNBT filed an S-1 registration with the SEC with the future plans all noted. When the S-1 gets approved they have financing approved for a minimum of $40M to be used if needed. Think of it as a line of credit. The S-1 could be approved ANY day.

3) The financing allows them to purchase a majority interest privately held company named Altucell who may have a treatment which may cure Type 1 Diabetes. This companies research is fairly advanced and additional trials are about ready to go once funding arrives. Why?
from Generex: "as part of our due diligence
process, we pinpointed specific, comparable deals that validate the huge value of the
ALTuCELL acquisition, as evidenced by the recently announced purchase of Semma
Therapeutics by Vertex Pharmaceuticals for close to a billion dollars."

4) Generex is spinning off NGIO and it should be trading on the Nazdaq within a few weeks. It will be owned by Generex shareholders as we have been awarded dividend shares and ~70% by Generex. NGIO has the coronavirus vaccine to develop and a vaccine it is currently studying for breast cancer. Prostate research is underway as well. Other research is pending the new funding. Regarding number 4, I should have mentioned Merck. No doubt you all know about Keytruda being huge in cancer. The Generex/NGIO breast cancer study is a combo of NGIO's AE37 and Merck's Keytruda.

5) One of Generex's subs has a number of test kits for various ailments is working on a coronavirus test kit NOW.

6) Another sub, Olaregen has a wound care product being sold in the VA system and producing significant NEW revenue for Generex as of the last 3 months.

7) It was just announced two of the other subs have had a 400% increse in sales of their medical products recently

Over the next few day I will tell you about the MSO, HMO,Type 2 diabetes treatment and more.

Count yourselves lucky to be here now just before the good stuff is going to come together. Flippers will look back and regret having sold quite soon.

Did I mention Generex has already filed for UPLISTING ON THE NAZDAQ for GNBT? Waiting on the S-1 to be approved and the financing to be put to work.

Finally: I don't think many day traders and particularly short sellers realize what they have gotten themselves into. Any day now there will be news of significance such as the NGIO spinout and valuation details. Aside from cancer research and the rest, GNBT/NGIO is in position number one for a coronavirus vaccine in China. They are about to sign a nice deal with upfront money which is sufficient to get the initial work done in all likelihood. Milestone payment, all the costs covered and 20% of the rev's. NGIO's vaccine technology is such that it can be ready faster than traditional vaccines and can be produced in huge volumes very fast. A successful vaccine will result in an tremendous revenue revenue stream and big pharma looking at NGIO as a buy out candidate. A coronavirus vaccine is worth billions worldwide if this disease becomes an annual contagion as many medical researchers believe.

-----------------------------------------------------------------

6 Feb, 2020

Generex restarts vaccine efforts, Co-Diagnostics launches coronavirus test

Generex Biotechnology Corp. said two of its subsidiaries are collaborating with third-party groups and government agencies to reactivate efforts to develop vaccines against pandemic viruses.

The company previously developed vaccines for severe acute respiratory syndrome, or SARS, which became a global epidemic in 2003.

Generex' unit NuGenerex Immuno-Oncology — formerly Antigen Express — is looking at its patented Ii-Key technology to generate peptide vaccines. The technology is clinically proven to activate the immune system against a number of viruses such as H5N1 avian influenza or bird flu virus.

NuGenerex Immuno-Oncology said clinical trials of Ii-Key peptide vaccines have shown that the vaccines are safe and have long-lasting immune responses. One early-stage trial tested a series of vaccine peptides for H5N1 bird flu virus in more than 120 participants.

The Generex unit noted that its peptide vaccines could potentially be used against the novel coronavirus infection, or 2019-nCoV, because bird flu has been identified in animals in Wuhan, China, the epicenter of the 2019-nCoV outbreak.

NuGenerex Diagnostics, or NGIO, another Generex unit, has developed the Express II rapid diagnostic testing platform, which can detect antigens, antibodies or other components found in infectious diseases, cancer and other medical conditions. NGDx is initiating a project to adopt the platform that will help develop a diagnostic test for the Wuhan coronavirus infection.

Miramar, Fla.-based Generex Biotechnology, is an integrated healthcare holding company offering patient-centric care solutions such as rapid diagnosis and personalized therapies.

NuGenerex Immuno-Oncology, which is being spun out of Generex as a separate public company, has an ongoing mid-stage clinical trial investigating its lead cancer vaccine AE37 in combination with Merck & Co. Inc.'s Keytruda cancer drug for the treatment of triple-negative breast cancer.

Meanwhile, Co-Diagnostics Inc. said its CoPrimer diagnostic test for 2019-nCoV is available for sale to laboratories, hospitals and institutions that need a solution to the pandemic.

The company announced on Jan. 23 that CoPrimer, a polymerase chain reaction test designed for research purposes only, met the requirements for detecting coronavirus.

Co-Diagnostics CEO Dwight Egan said leveraging the company's proprietary design process and software has allowed it to quickly move the product from design to commercialization.

On Jan. 30, the World Health Organization declared the novel coronavirus a global health emergency. The U.S. Food and Drug Administration on Feb. 4 authorized the emergency use of in vitro diagnostic tests for the virus — those done on samples taken from the human body — due to its potential to negatively impact national security or public health.

Salt Lake City's Co-Diagnostics is a molecular diagnostics company that offers reagents used for diagnostic tests that can detect and analyze nucleic acid molecules.

------------------------------------------------------------------

https://www.newsbreak.com/info/generex-biotechnology-corporation

https://www.marketbeat.com/stocks/OTCMKTS/GNBT/

-----------------------------------------------------------------

https://www.modernreaders.com/news/2020/01/26/critical-review-soligenix-nasdaqsngx-vs-generex-biotechnology-nasdaqgnbt.html

Comparatively, 35.2% of Generex Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

----------------------------------------------------------------